Примери за използване на Paediatric investigation на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Paediatric investigation plans.
Modification of a paediatric investigation plan.
Paediatric investigation plans.
Compliance with the paediatric investigation plan.
The paediatric investigation plan should be the basis upon which compliance with that requirement is judged.
Modification of a paediatric investigation plan.
To assess the content of any paediatric investigation plan for a medicinal product submitted to it in accordance with this Regulation and formulate an opinion thereon;
Compliance with the agreed paediatric investigation plan.
A paediatric investigation plan was authorised, to that effect, by the competent authority on 27 March 2009 and the studies prescribed in that plan must be completed by 2017.
EMA receives the 1,000th application for a paediatric investigation plan(PIP) or waiver.
Merck points out that a paediatric investigation plan was authorised by the competent authority on 27 March 2009 and that the studies prescribed in that plan must be completed by 2017.
The application shall also include the decision of the Agency agreeing the paediatric investigation plan concerned.
It is appropriate to set a deadline for the submission of a paediatric investigation plan in order to ensure early dialogue between the sponsor and the Paediatric Committee.
The application shall also include the decision of the Agency agreeing the paediatric investigation plan concerned.
The paediatric investigation plan should include details of the timing and the measures proposed to demonstrate the quality, safety and efficacy of the medicinal product in the paediatric population.
The EMEA Paediatric Committee will conduct assessment of, agreement on, andverification of compliance with, paediatric investigation plans and waivers.
In addition, the work on paediatric investigation plans will impact on activities within other areas, including scientific advice, quality and post-authorisation areas, as well as risk-management plans.
The Paediatric Regulation gives the EMA andits Paediatric Committee primary responsibility for handling paediatric investigation plans, deferrals and waivers.
Furthermore, early submission of a paediatric investigation plan, combined with the submission of a deferral request as described below, will avoid delaying the authorisation for other populations.
The Paediatric Committee should be primarily responsible for the scientific assessment and agreement of paediatric investigation plans and for the system of waivers and deferrals thereof;
The paediatric investigation plan shall specify the timing and the measures proposed to assess the quality, safety and efficacy of the medicinal product in all subsets of the paediatric population that may be concerned.
The Agency shall inform the competent authority if it is found that the marketing authorisation holder has failed to comply with the decision of the Agency agreeing the paediatric investigation plan and granting a deferral.
Thus, paediatric investigation plans should be submitted early during product development, in time for studies to be conducted in the paediatric population, where appropriate, before marketing authorisation applications are submitted.
The Paediatric Committee(PDCO) is responsible for assessing the content of applications for paediatric investigation plans, waivers, deferrals and compliance checks, and adopting opinions on them.
With the support of the national competent authorities the Agency succeeded in establishing the Paediatric Committee(PDCO)- the Agency's fifth scientific committee- andputting in place the necessary procedures for the assessment of paediatric investigation plans(PIPs) and waiver applications.
Guideline on the format andcontent of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies.
The Paediatric Committee- the Agency's fifth scientific committee- was launched with great enthusiasm in July of this year, and immediately began to elaborate scientific andprocedural arrangements for the assessment of paediatric investigation plans and related regulatory instruments.
An agreed paediatric investigation plan may lead to information on the paediatric use of medicines being included in a centralised or national marketing authorisation for new medicinal products, and in a paediatric-use marketing authorisation for offpatent products.
The Paediatric Committee(PDCO) is responsible for assessing the content of applications: for paediatric investigation plans, with or without request of deferral(s) and/or partial waivers; for modification of a previously agreed paediatric investigation plan; for product-specific waivers and for compliance checks.